Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PKM | P14618 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7463097 | 0.83 | — | — | |
| SCHEMBL7461807 | 0.73 | — | — | |
| SCHEMBL19766523 | 0.73 | — | — | |
| SCHEMBL7460167 | 0.73 | — | — | |
| SCHEMBL31424275 | 0.73 | — | — | |
| SCHEMBL14695704 | 0.71 | TSHR (0.40) | — | |
| SCHEMBL7455936 | 0.71 | — | — | |
| SCHEMBL17586258 | 0.69 | — | — | |
| SCHEMBL17586260 | 0.69 | — | — | |
| SCHEMBL12121209 | 0.67 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230322785-A1 | ADENOSINE A2A AND A2B RECEPTOR DUAL ANTAGONISTS FOR IMMUNO-ONCOLOGY | MERCK SHARP & DOHME LLC (US) | 2023-10-12 | — | — | US | disclosed |
| WO-2016044331-A1 | BICYCLIC COMPOUNDS | KALYRA PHARMACEUTICALS, INC. (US) | 2016-03-24 | — | — | WO | disclosed |
| US-20160075654-A1 | BICYCLIC COMPOUNDS | RECURIUM IP HOLDINGS, LLC | 2016-03-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160075654-A1 | BICYCLIC COMPOUNDS | OPRK1, OPRM1, OPRL1 | PKM 2397/4885 |
| US-20230322785-A1 | ADENOSINE A2A AND A2B RECEPTOR DUAL ANTAGONISTS FOR IMMUNO-ONCOLOGY | ADORA2A, ADORA2B, ADORA1 | PKM 3692/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.